03-26-2006, 07:01 AM
|
 |
Registered User
|
|
Join Date: Mar 2006
Posts: 5
Thanks: 0
Thanked 1 Time in 1 Post
|
|
|
A prospective randomized trial toward a "blood transfusion"-free hepatectomy.
Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy.
Ann Surg. 2006; 243(2):173-80 (ISSN: 0003-4932)
Wu CC; Ho WM; Cheng SB; Yeh DC; Wen MC; Liu TJ; P'eng FK Department of Surgery, Taichung Veterans General Hospital, and Department of Surgery, Chung-Shan Medical University, Taichung, Taiwan. he@vghtc.gov.tw
OBJECTIVE: To examine the feasibility of a real "blood transfusion"-free hepatectomy in a large group of patients with liver tumors.
SUMMARY BACKGROUND DATA: Bleeding control and blood transfusion remains problematic in liver resection. A real "blood transfusion"-free hepatectomy in a large group of patients has rarely been reported. The impact of tranexamic acid (TA), an antifibrinolytic agent, on blood transfusion in liver resection is unknown.
METHODS: A prospective double-blind randomized trial was performed on elective liver tumor resections. In group A, TA 500 mg was intravenously administered just before operation followed by 250 mg, every 6 hours, for 3 days. In group B, only placebo was given. The patients' background, blood transfusion rates, and early postoperative results in the 2 groups were compared. Factors that influenced blood requirement were analysed.
RESULTS: There were 108 hepatectomies in group A and 106 hepatectomies in group B. The patients' backgrounds, operative procedures, and hepatectomy extent did not significantly differ between the 2 groups. Although the differences of the operative morbidity and postoperative stay were not significant, a significantly lower amount of operative blood loss, lower blood transfusion rate, shorter operative time, and lower hospital costs were found in group A patients. No patient in group A received blood transfusion. No hospital mortality occurred in either group. Tumor size and use of TA were independent factors that influenced blood transfusion.
CONCLUSIONS: Perioperative parenteral use of TA reduced the amount of operative blood loss and the need for blood transfusion in elective liver tumor resection. A real "blood transfusion"-free hepatectomy may be feasible with the assistance of parenteral TA.
PreMedline Identifier: 16432349
|
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
